60% achieved 20% or more, 23% achieved 30% or more
Pediatr Crit Care Med 13(Suppl 1):S1S82 Kochanek PM, Jackson TC, Ferguson NM, Carlson SW, Simon DW, Brockman EC, Ji J, Bayir H, Poloyac SM, Wagner AK, Kline AE, Empey PE, Clark RS, Jackson EK, Dixon CE (2015) Emerging therapies in traumatic brain injury
Should patients with a history of blood clots avoid using Ozempic
In contrast, 2% of people in the placebo group noticed an increase in anxiety
There is no established evidence that semaglutide triggers Crohn's flares, but its gastrointestinal side effects (nausea, diarrhea, abdominal pain) can overlap with and potentially mask disease symptoms
Body Mass Index (BMI): Sitagliptin phosphate: Body mass index (BMI) had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data